Our latest podcast is now available from the Stanford Talks site (and below).  In this episode: (1) CLB director Hank Greely discusses recent attempts to introduce FMRI-based lie detection as courtroom evidence; (2) CLB Fellow Jake Sherkow analyzes a recent appellate court decision about “pay to delay” settlements between name brand drug companies and generic manufacturers; and (3) CLB Fellow Matt Lamkin argues against proposals to expand regulatory oversight of “enhancement” technologies.  Watch this space for more CLB podcasts in the coming months.

[audio:http://talks.stanford.edu/video/law/clb/podcast/CLB_podcast_09-13-2012.mp3]